- Home
- REE vs INAB Comparison
REE vs INAB Comparison
Compare REE & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REE | INAB |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1M | 22.9M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | REE | INAB |
|---|---|---|
| Price | $0.60 | $1.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $11.75 | ★ $180.00 |
| AVG Volume (30 Days) | ★ 49.8K | 31.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $327.73 | N/A |
| Revenue Next Year | $36,888.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $0.12 |
| 52 Week High | $6.60 | $4.20 |
Technical Indicators
Market Signals| Indicator | REE | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 48.69 | 53.00 |
| Support Level | $0.53 | $1.52 |
| Resistance Level | $0.75 | $2.15 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 40.08 | 67.59 |
Price Performance
Historical ComparisonAbout REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.